September 5th-9th: Defymed at the conference of the European Society for Biomaterials
Last year Defymed attended for the first time to the World Biomaterials Congress which held on December 11-15, 2020 via an excellent virtual platform.
This year Defymed confirms its strong interest on biomaterials, improvement performed to process them and how they could be used in conjunction with other technologies by participating to the 31st Conference of the European Society for Biomaterials. Initially programmed as a hybrid conference (on-site and online), the event moved to a fully virtual participation due to the delta variant infections. Despite that fact, Defymed is sure that the conferences that will be held on September 5-9, 2021 will be a great success with hot and immersive topics.
Indeed, biomaterials such as chitosan, hyaluronic acid, and silk fibroin are extensively used in biomaterial applications because those polymers are naturally-derived polymers which own biocompatibility properties (e.g. non-antigenicity or on-toxicity) but also thanks to their chemical and physical properties.
As a medical device manufacturer, biomaterials represent a promising and an exciting field since they could also be used in combination with other materials to carry and/or apply drugs to a disease target. Biomaterials could be used to control biological function, particularly the differentiation of stem cells or combine as biomaterial supports or scaffolds with cells and /or bioactive molecules.
Immunomodulating biomaterials may help to tackle widespread chronic diseases such as type 1 diabetes, for which Defymed focuses since the last decade in the development of MailPan® and ExOlin®.
In other words, biomaterials could be used on or within our medical devices to improve their integration to the human body, to specifically target organs or tissues, to give a support for cells function or differentiation, to minimize the size of our devices to be suitable for minimally invasive surgery.